Browse the corpus

REFERENCES Anne PR and Curran WJ Jr, “A Phase II Trial of Subcutaneous Amifostine and Radiation Therapy in Patients With Head and Neck Cancer,” Semin Radiat Oncol , 2002, 12(1 Suppl 1):18-9. [PubMed 11917279 ] Bonner HS and Shaw LM, “New Dosing Regimens for Amifostine: A Pilot Study to Compare the Relative Bioavailability of Oral and Subcutaneous Administration With Intravenous Infusion,” J Clin Pharmacol , 2002, 42(2):166-74. [PubMed 11831539 ] Brizel DM, Wasserman TH, Henke M, et al, “Phase III Randomized Trial of Amifostine as a Radioprotector in Head and Neck Cancer,” J Clin Oncol , 2000, 18(19): 3339-45. [PubMed 11013273 ] Capizzi RL and Oster W, “Chemoprotective and Radioprotective Effects of Amifostine: An Update of Clinical Trials,” Int J Hematol , 2000, 72(4):425-35. [PubMed 11197208 ] Culy CR and Spencer CM, “Amifostine: An Update on Its Clinical Status as a Cytoprotectant in Patients With Cancer Receiving Chemotherapy or Radiotherapy and Its Potential Therapeutic Application in Myelodysplastic Syndrome,” Drugs , 2001, 61(5):641-84. [PubMed 11368288 ] Hensley ML, Hagerty KL, Kewalramani T, et al, “American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiotherapy Protectants,” J Clin Oncol , 2009, 27(1): 127-45. [PubMed 19018081 ] Keefe DM, Schubert MM, Elting LS, et al, “Updated Clinical Practice Guidelines for the Prevention and Treatment of Mucositis,” Cancer , 2007, 109(5): 820-31. [PubMed 17236223 ] Koukourakis MI, Kyrias G, and Kakolyris S, “Subcutaneous Administration of Amifostine During Fractionated Radiotherapy: A Randomized Phase II Study,” J Clin Oncol , 2000, 18(11):2226-33. [PubMed 10829042 ] Norales G, Maria V, de Guzman A, et al, “Amifostine-Induced Back Pain: a Case Report,” Am J Health-Syst Pharm , 2006, 63(4): 381-2. Peterson DE, Bensadiun RJ, and Roila F, “Management of Oral and Gastrointestinal Mucositis: ESMO Clinical Recommendations,” Ann Oncol , 2008, 19(Suppl 2): 122-5. [PubMed 18456749 ] Samuels MA, Chico IM, Hirsch RL, et al, “Ongoing Prospective Multicenter Safety Study of the Cytoprotectant Amifostine Given Subcutaneously: Overview of Trial Design,” Semin Oncol , 2003, 30(6 Suppl 18):94-5.

Peterson DE, Bensadiun RJ, and Roila F, “Management of Oral and Gastrointestinal Mucositis: ESMO Clinical Recommendations,” Ann Oncol , 2008, 19(Suppl 2): 122-5. [PubMed 18456749 ] Samuels MA, Chico IM, Hirsch RL, et al, “Ongoing Prospective Multicenter Safety Study of the Cytoprotectant Amifostine Given Subcutaneously: Overview of Trial Design,” Semin Oncol , 2003, 30(6 Suppl 18):94-5. Spencer CM and Goa KL, “Amifostine. A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential as a Radioprotector and Cytotoxic Chemoprotector,” Drugs , 1995, 50(6):1001-31. [PubMed 8612469 ] Wasserman TH and Brizel DM, “The Role of Amifostine as a Radioprotector,” Oncology (Huntingt) , 2001, 15(10):1349-54. Topic 8533 Version 37.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.3 - C21.34 Licensed to: Morehouse School of Medicine | Support Tag: [1103-200.150.3.100-EF161DC620-S473950.14]